Drugs / BG-60366
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06685718 | Dec 2024 → Apr 2026 | non-small cell lung carcinoma | BeOne Medicines | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BG-60366 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06685718 ↗ |
| Modality | Other / unclassified | “a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC)” NCT06685718 ↗ |
| Route | Oral | “Administered orally” NCT06685718 ↗ |
| Target | EGFR | “BG-60366 is designed to degrade mutant EGFR” NCT06685718 ↗ |